Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Inks Distribution Deal with Fluxion Biosciences

NEW YORK (GenomeWeb News) – Molecular Devices today announced a global distribution agreement with Fluxion Biosciences covering its IonFlux instruments and consumables.

Molecular Devices also is providing support for all IonFlux Systems users as part of the deal, it said.

Financial and other terms of the deal were not disclosed.

South San Francisco, Calif.-based Fluxion provides tools for cellular analysis. Its portfolio includes instruments for live cell imaging and the analysis of circulating tumor cells. The Ion Flux is for automated patch clamping.

Sunnyvale, Calif.-based Molecular Devices is a Danaher company and provides bioanalytical measurement systems, software, and consumables, including products for high-throughput screening, and genomic and cellular analysis.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.